- Teva Pharmaceuticals (NYSE: TEVA) gross profits rose by six percent in Q2, 2021.
- Infinity Pharmaceuticals (Nasdaq: INFI) incurred losses of US$11.3 million in Q2.
- Teladoc Health Inc. (NYSE: TDOC) reported a net loss of US$133.8 million in Q2.
Many healthcare companies, including several top drugmakers, released their second-quarter earnings this week. And stocks of some of these companies have seen a surge in prices following the results.
Companies in the healthcare sector comprise different enterprises, from drugmakers to firms providing healthcare services or manufacturing medical devices. They are also into research projects for drug development.
Here we explore three trending pharmaceutical stocks that announced their Q2 earnings this week.
What do Infinity Pharma’s earnings say?
Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) preented its Q2 earnings report on July 27. The company had US$97.3 million in liquidity reserves compared to US$106.8 million in Q2, 2020.
The pharma company incurred losses of US$11.3 million or US$0.13 per diluted share in this quarter. The net losses were US$9.5 million or US$0.16 diluted per share in Q2, 2020.
Following the results, the stock of INFI shoot up by 47.70 percent to US$2.245 on July 28. The market capitalization of the company is US$200 million, and the EPS is US$-0.61. The lowest and highest stock price for the last 52 weeks is US$0.82 and US$5.98.
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) released its second-quarter earnings on July 28. The revenue of the Israel-based company in the quarter is US$3.9 billion. Diluted EPS is US$0.19. The company’s cash flow from operations was US$218 million. The gross profit is US$1.8 billion, up by 6 percent YoY. Net income is US$207 million compared to US$140 million of Q2, 2020. Following the earnings report, the stock surged by 12.33 percent to US$10.02 at 11.31 am ET on July 28.
The company produces generic and unique medicines in 3500 categories. The market capitalization of the pharma company is US$11 billion. The EPS is US$3.63. The share volume is 22,201,169.
Teladoc’s Q2 earnings
Teladoc Health Inc (NYSE: TDOC) released the second-quarter earnings on July 27. The revenue of the pharma company grew by 109 percent YoY to US$503 million.
The company reported a net loss of US$133.8 million or US$0.86 per diluted share in the quarter compared to US$25.7 million or US$0.34 per diluted share in Q2, 2020.
The gross margin is US467.9 percent compared to 61.7 percent in Q2, 2020. Adjusted EBITDA represented a loss of US$27.6 million compared to a profit of US$2.7 million in Q2, 2020.
Also read: 10 cheap pharma stocks to explore as pandemic weakens
The stock of TDOC was up 0.77 percent to US$149.76 at 12.03 pm ET on July 28. The market capitalization of the company is US$22 billion. The EPS is US$5.67, and the beta is 0.27. The share volume is 8,283,403.
Please note: The above constitutes a preliminary view, and any interest in stocks/cryptocurrencies should be evaluated further from an investment point of view.